78183-55-8

Usage

Uses

Used in Pharmaceutical Research and Development:
(S)-1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACID METHYL ESTER HYDROCHLORIDE is used as a research compound for its potential analgesic, neuroprotective, and anti-inflammatory properties, making it a candidate for the development of new medications targeting pain relief, neurodegenerative diseases, and inflammatory conditions.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (S)-1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACID METHYL ESTER HYDROCHLORIDE serves as a valuable tool for studying the structure-activity relationships of tetrahydroisoquinoline derivatives, aiding in the design and optimization of novel therapeutic agents.
Used in Drug Discovery:
(S)-1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACID METHYL ESTER HYDROCHLORIDE is utilized in drug discovery efforts to identify and develop new pharmaceutical agents with potential therapeutic benefits, particularly in the areas of pain management, neuroprotection, and inflammation control.
Note: Since the provided materials do not specify different applications in various industries, the uses listed are general and pertain to the broader field of pharmaceuticals and medicinal chemistry. If there are specific applications in different industries, they would need to be detailed in the materials provided.

Upstream product

• 67-56-1 methanol 
• 74163-81-8 L-Tic-OH 
• 116174-78-8 benzyl (S)-1,2,3,4-tetrahydro-2-pivaloyl-isoquinoline-3-carboxylate 
• 77497-96-2 (S)-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, phenylmethylester 
• 63-91-2 L-phenylalanine 
• 77497-95-1 (3S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid hydrochloride 
• 116174-79-9 (3S)-1,2,3,4-tetrahydro-2-pivaloylisoquinoline-3-carboxylic acid 

Downstream Products

• 133211-48-0 (10aS)-2-ethyl-3-thioxo-1,2,3,5,10,10a-hexahydroimidazo[1,5-b]isoquinoline-1-one 
• 133211-48-0 2-ethyl-3-thioxo-1,2,3,5,10,10a-hexahydroimidazo[1,5-b]isoquinoline-1-one 
• 929207-35-2 methyl (3S)-N-[(1S)-1-methylbenzyl]carbamoyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylate 
• 929207-36-3 methyl (3S)-N-cyclohexylcarbamoyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylate 
• 929207-33-0 methyl (3S)-N-phenylcarbamoyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylate 
• 133211-51-5 (10aS)-2-phenyl-3-thioxo-1,2,3,5,10,10a-hexahydroimidazo[1,5-b]isoquinoline-1-one 
• 133211-51-5 2-phenyl-3-thioxo-1,2,3,5,10,10a-hexahydroimidazo[1,5-b]isoquinoline-1-one 
• 166169-43-3 (R*)-N-amino>-3-<(triphenylmethyl)thio>propyl>-N-(benzyloxycarbonyl)-L-valyl>-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid methyl ester 
• 166169-81-9 (S)-1,2,3,4-tetrahydro-2-<3-methyl-N-<(phenylmethoxy)-carbonyl>-L-valyl>-3-isoquinolinecarboxylic acetic acid, methyl ester 
• 127413-80-3 (S)-2-[(R)-4-((S)-2-Benzyloxycarbonylamino-6-tert-butoxycarbonylamino-hexanoylamino)-4-ethoxycarbonyl-butyryl]-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester 
• 762245-26-1 (S)-2-(4-benzyloxy-5-methoxy-2-nitrobenzoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid methyl ester 

Relevant academic research and scientific papers

COMPOSITIONS AND METHODS RELATED TO MOLECULAR CONJUGATION

The invention relates to activated Michael acceptor (AMA) compounds that can undergo conjugation with biomolecules containing Michael donor moieties, thereby providing plasma-stable antibody-drug conjugates (ADCs). Pharmaceutical compositions of the ADCs are disclosed as well. Also provided herein are a number of applications (e.g., therapeutic applications) in which the compositions are useful.

ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-B7-H3 ANTIBODIES

The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-B7-H3 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind B7-H3, as well as methods of making and using these anti-B7-H3 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications

FUSED HETEROCYCLIC BENZODIAZEPINE DERIVATIVES AND USES THEREOF

The present disclosure provides compounds and compositions capable of extending lifespan, and methods of use thereof.

NOVEL BENZODIAZEPINE DERIVATIVES AND USES THEREOF

The present disclosure provides compounds and compositions capable of extending lifespan, and methods of use thereof.

SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS

Disclosed are compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein: W and Q and G are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bcl-2 family antiapoptotic proteins for the treatment of cancer; and pharmaceutical compositions comprising such compounds.

Dynamic combinatorial chemistry with hydrazones: Libraries incorporating heterocyclic and steroidal motifs

We expand the possibilities in hydrazone based dynamic combinatorial chemistry with a series of new building blocks incorporating heterocyclic motifs. The synthetic procedure allows efficient access to building blocks with the general structure (MeO)2CH-Heterocycle-C(O)NHNH2, originating from heterocycles with an amine and an ester functionality. The equilibrium distribution of macrocyclic N-acyl hydrazones formed upon deprotection of the building blocks with TFA in organic solvents is reported. The mixing behaviour of these heterocycle-based building blocks with our cholate-based building blocks is described, particularly the observation of kinetic intermediates that disappear following 'proof-reading'. The Royal Society of Chemistry.

Synthesis of tetrahydroisoquinoline-diamine ligands and their application in asymmetric transfer hydrogenation

The use of the tetrahydroisoquinoline scaffold is well documented in biologically active compounds. However, reports of the utilisation of tetrahydroisoquinoline compounds in asymmetric catalysis are limited. The synthesis of novel diamine ligands possessing the tetrahydroisoquinoline (tetrahydroisoquinoline) backbone and evaluation of their activity in the asymmetric transfer hydrogenation of acetophenone are presented. The diamine ligands in conjunction with i-PrOH as the hydrogen source and [RhCl2(Cp*)]2 as the metal precursor proved to be the most effective of the tetrahydroisoquinoline derivatives for this catalytic system. Water was found to have a profound influence on the enantioselectivity of the reaction. Optimisation of the amount water, i-PrOH and catalytic loading content rendered the best result of 70% enantioselectivity for the (S)-1-phenylethanol isomer product.

Efficient synthesis and structural analysis of new dioxopiperazine isoquinolines

We report herein the synthesis of new dioxopiperazine isoquinolines using the Pictet-Spengler cyclisation. Our synthetic strategy for the preparation of two new compounds (5, 6), with a tetrahydro-6H-pyrazino[1,2-b]isoquinoline-1,4-dione moiety was developed in only four steps. To understand better the crucial step of the synthesis reported here, theoretical calculations using semiempirical (PM3), ab initio and DFT computations were carried out on a reduced system model. The structure of chlorohydrate water solvate of tetrahydro (2-piperidinylethyl)-6H-pyrazino [1,2-b]isoquinoline-1,4-dione (6·HCl·2H2O) was determined by X-ray diffraction. Theoretical calculations (RHF/3-21G and RB3LYP/6-31G(d)) were also performed for compound 6 neutralised with a chloride ion.

Hydantoins and thiohydantoins derived from 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid

The reaction of methyl (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate with isocyanates (phenyl, naphthalen-l-yl, cyclohexyl, (S)-1-methylbenzyl) in ether has been used to prepare N-substituted methyl (3S)-2-aminocarbonyl-1,2,3,4-tetrahydroisoquinoline-3

ENZYME INHIBITORS

Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers, wherein R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R2is the side chain of a natural or non-natural alpha amino acid; Y is a bond, -C(=O)-, -S(=O)2-, -C(=O)O-, -C(O)NR3-, -C(=S)-NR3 , -C(=NH)NR3 or -S(=O)2NR3- wherein R3 is hydrogen or optionally substituted C1-C6 alkyl; L1 is a divalent radical of formula -(Alk1)m(Q)n(Alk2)p- wherein m, n and p are independently 0 or 1 , Q is (i) an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5 - 13 ring members, or (ii), in the case where both m and p are 0, a divalent radical of formula -X2-Q1- or -Q1-X2- wherein X2 is -O-, S- or NRA- wherein RA is hydrogen or optionally substituted C1-C3 alkyl, and Q1 is an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5 - 13 ring members, AIk1 and AIk2 independently represent optionally substituted divalent C3-C7 cycloalkyl radicals, or optionally substituted straight or branched, C1-C6 alkylene, C2-C6 alkenylene ,or C2-C6 alkynylene radicals which may optionally contain or terminate in an ether (-O-), thioether (-S-) or amino (-NRA-) link wherein RA is hydrogen or optionally substituted C1-C3 alkyl; X1 represents a bond; -C(=O); or -S(=O)2-; -NR4C(=O)-, -C(=O)NR4-, -NR4C(=O)NR5- , -NR4S(=O)2-, or -S(=O)2NR4-wherein R4 and R5 are independently hydrogen or optionally substituted C1-C6 alkyl; z is 0 or 1 ; A represents an optionally substituted mono-, bi- or tri-cyclic carbocyclic or heterocyclic ring system wherein the radicals R1R2NH-Y-L1-X1-[CH2]Z- and HONHCO-[LINKER]- are attached different ring atoms; and -[Linker]- represents a divalent linker radical linking a ring atom in A with the hydroxamic acid group CONHOH, the length of the linker radical, from the terminal atom linked to the ring atom of A to the terminal atom linked to the hydroxamic acid group, is equivalent to that of an unbranched saturated hydrocarbon chain of from 3-10 carbon atoms.